Capitol Health Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Capitol Health wird ein jährliches Gewinn- und Umsatzwachstum von 38.1% bzw. 5.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 37.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.2% betragen.

Wichtige Informationen

69.2%

Wachstumsrate der Gewinne

70.6%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	26.0%
Wachstumsrate der Einnahmen	6.3%
Zukünftige Eigenkapitalrendite	15.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 05

Have Insiders Been Selling Capitol Health Limited (ASX:CAJ) Shares This Year?

Feb 14

Did You Miss Capitol Health's (ASX:CAJ) 20% Share Price Gain?

Jan 19

Is Capitol Health Limited's (ASX:CAJ) Shareholder Ownership Skewed Towards Insiders?

Dec 22

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Dec 01

Here's Why We Don't Think Capitol Health's (ASX:CAJ) Statutory Earnings Reflect Its Underlying Earnings Potential

Aug 17

Is Now An Opportune Moment To Examine Capitol Health Limited (ASX:CAJ)?

Jul 25

Is Capitol Health Limited's (ASX:CAJ) Latest Stock Performance A Reflection Of Its Financial Health?

Jul 04

Gewinn- und Umsatzwachstumsprognosen

ASX:CAJ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	284	19	21	50	7
6/30/2026	268	16	19	45	9
6/30/2025	252	13	15	39	8
6/30/2024	235	-15	17	36	N/A
3/31/2024	232	-5	14	36	N/A
12/31/2023	229	6	12	36	N/A
9/30/2023	219	-3	16	37	N/A
6/30/2023	210	-12	21	37	N/A
3/31/2023	198	-12	18	33	N/A
12/31/2022	187	-12	16	28	N/A
9/30/2022	186	-1	18	30	N/A
6/30/2022	184	11	19	32	N/A
3/31/2022	186	12	22	34	N/A
12/31/2021	188	14	26	36	N/A
9/30/2021	183	13	29	39	N/A
6/30/2021	178	12	33	41	N/A
3/31/2021	168	8	33	43	N/A
12/31/2020	159	4	34	45	N/A
9/30/2020	156	3	28	40	N/A
6/30/2020	154	1	23	35	N/A
3/31/2020	156	8	18	30	N/A
12/31/2019	157	15	12	25	N/A
9/30/2019	153	20	8	22	N/A
6/30/2019	149	24	4	18	N/A
12/31/2018	137	-2	5	15	N/A
9/30/2018	128	-6	4	13	N/A
6/30/2018	119	-11	4	11	N/A
12/31/2017	110	2	N/A	15	N/A
9/30/2017	108	2	N/A	15	N/A
6/30/2017	107	2	N/A	15	N/A
12/31/2016	80	1	N/A	13	N/A
9/30/2016	92	2	N/A	13	N/A
6/30/2016	104	2	N/A	13	N/A
3/31/2016	148	-2	N/A	15	N/A
12/31/2015	139	1	N/A	13	N/A
9/30/2015	125	3	N/A	14	N/A
6/30/2015	110	4	N/A	16	N/A
3/31/2015	103	6	N/A	16	N/A
12/31/2014	95	9	N/A	16	N/A
9/30/2014	92	8	N/A	14	N/A
6/30/2014	90	7	N/A	12	N/A
3/31/2014	83	6	N/A	10	N/A
12/31/2013	77	5	N/A	7	N/A
9/30/2013	70	4	N/A	7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CAJ wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: CAJ wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CAJ wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CAJDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.2% pro Jahr).

Hohe Wachstumseinnahmen: CAJDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CAJDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.2%).

Capitol Health Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.1% to AU$0.31

Capitol Health Limited Provides Earnings Guidance for the Year 2025

Price target decreased by 9.8% to AU$0.28

Price target decreased by 9.6% to AU$0.33

Price target increased to AU$0.43

Consensus EPS estimates fall by 12%

Recent updates

Final dividend of AU$0.004 announced

Price target increased by 7.1% to AU$0.31

Full year 2024 earnings released: AU$0.014 loss per share (vs AU$0.011 loss in FY 2023)

Capitol Health Limited Provides Earnings Guidance for the Year 2025

Capitol Health Limited to Report Fiscal Year 2024 Results on Aug 22, 2024

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Calculating The Fair Value Of Capitol Health Limited (ASX:CAJ)

Now 21% undervalued after recent price drop

Now 21% undervalued

First half dividend of AU$0.005 announced

First half 2024 earnings released: EPS: AU$0.002 (vs AU$0.015 loss in 1H 2023)

New major risk - Financial position

Now 20% undervalued

Capitol Health Limited to Report First Half, 2024 Results on Feb 29, 2024

Capitol Health Limited Appoints Brendon Pentland as the Chief Financial Officer, Effective 1 April 2024

Capitol Health Limited's (ASX:CAJ) Popularity With Investors Is Clear

Capitol Health (ASX:CAJ) Takes On Some Risk With Its Use Of Debt

Now 21% undervalued

Now 21% undervalued after recent price drop

Capitol Health Limited Announces the Resignation of Craig Bremner as Chief Financial Officer

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Price target decreased by 9.8% to AU$0.28

Capitol Health Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings: EPS misses analyst expectations

Capitol Health Limited to Report Fiscal Year 2023 Results on Aug 24, 2023

Price target decreased by 9.6% to AU$0.33

Capitol Health Limited to Report First Half, 2023 Results on Feb 23, 2023

Now 21% undervalued

Now 21% undervalued

Capitol Health Limited (ASX:CAJ) completed the acquisition of Future Medical Imaging Group Pty Ltd.

Is Capitol Health Limited (ASX:CAJ) Worth AU$0.3 Based On Its Intrinsic Value?

Capitol Health Limited Declares Franked Dividend for the Six Months Ended June 30, 2022, Payable on October 21, 2022

Price target increased to AU$0.43

Capitol Health Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings: EPS misses analyst expectations

Capitol Health Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 21 October, 2022

Consensus EPS estimates fall by 12%

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Capitol Health Limited Announces Dividend for the Six Months Ended December 31, 2021, Payable on April 1, 2022

Capitol Health Limited to Report First Half, 2022 Results on Feb 24, 2022

Full year 2021 earnings released: EPS AU$0.012 (vs AU$0.001 in FY 2020)

Capitol Health (ASX:CAJ) Seems To Use Debt Rather Sparingly

Should You Investigate Capitol Health Limited (ASX:CAJ) At AU$0.37?

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Analysts increase EPS estimates to AU$0.012

First half 2021 earnings released: EPS AU$0.006 (vs AU$0.004 in 1H 2020)

Price target raised to AU$0.36

New 90-day high: AU$0.34

Have Insiders Been Selling Capitol Health Limited (ASX:CAJ) Shares This Year?

Capitol Health Limited (ASX:CAJ) acquired Direct Radiology.

Capitol Health Limited to Report First Half, 2021 Results on Feb 24, 2021

New 90-day high: AU$0.28

Did You Miss Capitol Health's (ASX:CAJ) 20% Share Price Gain?

Is Capitol Health Limited's (ASX:CAJ) Shareholder Ownership Skewed Towards Insiders?

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Price target raised to AU$0.31

Capitol Health Limited (ASX:CAJ) entered into a binding agreement to acquire Direct Radiology for AUD 12 million.

Capitol Health Limited (ASX:CAJ) entered into a binding agreement to acquire Direct Radiology for AUD 12 million.

New 90-day high: AU$0.27

Capitol Health Limited Appoints Craig Bremner as Chief Financial Officer, November 9, 2020

Capitol Health Limited Announces Resignation of Marcell Judkins as Chief Financial Officer

Price target raised to AU$0.27

Capitol Health Limited (ASX:CAJ) completed the acquisition of 90% stake in Fowler Simmons Radiology.

Here's Why We Don't Think Capitol Health's (ASX:CAJ) Statutory Earnings Reflect Its Underlying Earnings Potential

Capitol Health Limited to Report Fiscal Year 2020 Results on Aug 26, 2020

Is Now An Opportune Moment To Examine Capitol Health Limited (ASX:CAJ)?

Is Capitol Health Limited's (ASX:CAJ) Latest Stock Performance A Reflection Of Its Financial Health?